https://orcid.org/0000-0001-7507-0423
Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Jonah Larkins-Ford & Bree B. Aldridge. (2023) Advances in the design of combination therapies for the treatment of tuberculosis. Expert Opinion on Drug Discovery 18:1, pages 83-97.
Read now
Read now
Articles from other publishers (29)
Sara Ahmed, Sultan Chowdhury, James Gomez, Deborah T. Hung & Tanya Parish. (2023)
Benzene Amide Ether Scaffold is Active against Non-replicating and Intracellular
Mycobacterium tuberculosis
. ACS Infectious Diseases.
Crossref
Crossref
Kristy R. Winkler, Valerie Mizrahi, Digby F. Warner & Timothy J. De Wet. (2023) High‐throughput functional genomics: A (myco)bacterial perspective. Molecular Microbiology 120:2, pages 141-158.
Crossref
Crossref
Junhao Zhu, Yue J Liu & Sarah M Fortune. (2023) Spatiotemporal perspectives on tuberculosis chemotherapy. Current Opinion in Microbiology 72, pages 102266.
Crossref
Crossref
Shilah Bonnett, Jo-Ann Jee, Somsundaram Chettiar, Yulia Ovechkina, Aaron Korkegian, Eric Greve, Joshua Odingo & Tanya Parish. (2023) Identification of 2-Amino Benzothiazoles with Bactericidal Activity against Mycobacterium tuberculosis. Microbiology Spectrum.
Crossref
Crossref
Sarbjit Singh Jhamb, Raman Preet Singh & Prati Pal Singh. 2023. Recent Advances in Pharmaceutical Innovation and Research. Recent Advances in Pharmaceutical Innovation and Research
669
712
.
Amala Bhagwat, Aditi Deshpande & Tanya Parish. (2022) How Mycobacterium tuberculosis drug resistance has shaped anti-tubercular drug discovery. Frontiers in Cellular and Infection Microbiology 12.
Crossref
Crossref
Anuradha Kumar, Somsundaram Chettiar, Brian S. Brown, Julie Early, Juliane Ollinger, Megan Files, Mai A. Bailey, Aaron Korkegian, Devon Dennison, Matthew McNeil, James Metz, Augustine Osuma, Michael Curtin, Aaron Kunzer, Gail Freiberg, Milan Bruncko, Dale Kempf & Tanya Parish. (2022) Novel chemical entities inhibiting Mycobacterium tuberculosis growth identified by phenotypic high-throughput screening. Scientific Reports 12:1.
Crossref
Crossref
Samuel Njikan, Sara Ahmed, Alyssa Manning, Divya Awasthi, Yulia Ovechkina, Sultan Chowdhury, Arielle Butts & Tanya Parish. (2022)
Chemical Exploration of a Highly Selective Scaffold with Activity against Intracellular
Mycobacterium tuberculosis
. Microbiology Spectrum 10:3.
Crossref
Crossref
Eric L. Nuermberger, Maria Santos Martínez-Martínez, Olalla Sanz, Beatriz Urones, Jorge Esquivias, Heena Soni, Rokeya Tasneen, Sandeep Tyagi, Si-Yang Li, Paul J. Converse, Helena I. Boshoff, Gregory T. Robertson, Gurdyal S. Besra, Katherine A. Abrahams, Anna M. Upton, Khisimuzi Mdluli, Gary W. Boyle, Sam Turner, Nader Fotouhi, Nicholas C. Cammack, Juan Miguel Siles, Marta Alonso, Jaime Escribano, Joel Lelievre, Joaquin Rullas-Trincado, Esther Pérez-Herrán, Robert H. Bates, Gareth Maher-Edwards, David Barros, Lluís Ballell & Elena Jiménez. (2022)
GSK2556286 Is a Novel Antitubercular Drug Candidate Effective
In Vivo
with the Potential To Shorten Tuberculosis Treatment
. Antimicrobial Agents and Chemotherapy 66:6.
Crossref
Crossref
Shahnawaz Majeed, Safiya Mehraj & Zahoor Ahmad. 2022. Drug Repurposing - Molecular Aspects and Therapeutic Applications. Drug Repurposing - Molecular Aspects and Therapeutic Applications.
Sebastian Schieferdecker, Freddy A. Bernal, K. Philip Wojtas, François Keiff, Yan Li, Hans-Martin Dahse & Florian Kloss. (2022) Development of Predictive Classification Models for Whole Cell Antimycobacterial Activity of Benzothiazinones. Journal of Medicinal Chemistry 65:9, pages 6748-6763.
Crossref
Crossref
Vasiliki Mavrikaki, Alexandros Pagonis, Isabelle Poncin, Ivy Mallick, Stéphane Canaan, Victoria Magrioti & Jean-François Cavalier. (2022) Design, synthesis and antibacterial activity against pathogenic mycobacteria of conjugated hydroxamic acids, hydrazides and O-alkyl/O-acyl protected hydroxamic derivatives. Bioorganic & Medicinal Chemistry Letters 64, pages 128692.
Crossref
Crossref
Saskia E. Mudde, Anna M. Upton, Anne Lenaerts, Hannelore I. Bax & Jurriaan E. M. De Steenwinkel. (2022) Delamanid or pretomanid? A Solomonic judgement!. Journal of Antimicrobial Chemotherapy 77:4, pages 880-902.
Crossref
Crossref
Ana C. Magalhães, Sara Ricardo, Ana C. Moreira, Mariana Nunes, Margarida Tavares, Ricardo J. Pinto, Maria Salomé Gomes & Luisa Pereira. (2022) InfectionCMA: A Cell MicroArray Approach for Efficient Biomarker Screening in In Vitro Infection Assays. Pathogens 11:3, pages 313.
Crossref
Crossref
Shasank S. Swain, Sanghamitra Pati & Tahziba Hussain. (2022) Quinoline heterocyclic containing plant and marine candidates against drug-resistant Mycobacterium tuberculosis: A systematic drug-ability investigation. European Journal of Medicinal Chemistry 232, pages 114173.
Crossref
Crossref
Summaya Perveen & Rashmi Sharma. (2022) Screening approaches and therapeutic targets: The two driving wheels of tuberculosis drug discovery. Biochemical Pharmacology 197, pages 114906.
Crossref
Crossref
Sara Ahmed, Alyssa Manning, Lindsay Flint, Divya Awasthi, Yulia Ovechkina & Tanya Parish. (2022) Identification of Novel Chemical Scaffolds that Inhibit the Growth of Mycobacterium tuberculosis in Macrophages. Frontiers in Pharmacology 12.
Crossref
Crossref
Sadaf Kalsum, Blanka Andersson, Jyotirmoy Das, Thomas Schön & Maria Lerm. (2021) A high-throughput screening assay based on automated microscopy for monitoring antibiotic susceptibility of Mycobacterium tuberculosis phenotypes. BMC Microbiology 21:1.
Crossref
Crossref
Antonia Molloy, James Harrison, John S. McGrath, Zachary Owen, Clive Smith, Xin Liu, Xin Li & Jonathan A. G. Cox. (2021) Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery. Microorganisms 9:11, pages 2330.
Crossref
Crossref
Jonah Larkins-Ford, Talia Greenstein, Nhi Van, Yonatan N. Degefu, Michaela C. Olson, Artem Sokolov & Bree B. Aldridge. (2021) Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis. Cell Systems 12:11, pages 1046-1063.e7.
Crossref
Crossref
Renata Jardim Etchart, Raoní S. Rambo, Bruno Lopes Abbadi, Nathalia Sperotto, Christiano Ev Neves, Fernanda Fries Silva, Maiele Dornelles, Lovaine Duarte, Fernanda Souza Macchi, Marcia Alberton Perelló, Rogério Vescia Lourega, Cristiano Valim Bizarro, Luiz Augusto Basso & Pablo Machado. (2021) Synthesis and Antimycobacterial Activity of 3-Phenyl-1H-indoles. Molecules 26:17, pages 5148.
Crossref
Crossref
Neeraja Subhash & Varadharajan Sundaramurthy. (2021) Advances in host‐based screening for compounds with intracellular anti‐mycobacterial activity. Cellular Microbiology 23:7.
Crossref
Crossref
Erik Hembre, Julie V. Early, Joshua Odingo, Catherine Shelton, Olena Anoshchenko, Junitta Guzman, Lindsay Flint, Devon Dennison, Matthew B. McNeil, Aaron Korkegian, Yulia Ovechkina, Paul Ornstein, Thierry Masquelin, Philip A. Hipskind & Tanya Parish. (2021) Novel Trifluoromethyl Pyrimidinone Compounds With Activity Against Mycobacterium tuberculosis. Frontiers in Chemistry 9.
Crossref
Crossref
Catherine D. Shelton, Matthew B. McNeil, Julie V. Early, Thomas R. Ioerger & Tanya Parish. (2021) Deletion of Rv2571c Confers Resistance to Arylamide Compounds in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 65:5.
Crossref
Crossref
Yossef Av-Gay, Giorgia Mori & Maria Rosalia Pasca. (2021) Editorial: New Approaches Against Drug-Resistant M. tuberculosis. Frontiers in Microbiology 12.
Crossref
Crossref
Pedro F. Dalberto, Eduardo V. de Souza, Bruno L. Abbadi, Christiano E. Neves, Raoní S. Rambo, Alessandro S. Ramos, Fernanda S. Macchi, Pablo Machado, Cristiano V. Bizarro & Luiz A. Basso. (2020) Handling the Hurdles on the Way to Anti-tuberculosis Drug Development. Frontiers in Chemistry 8.
Crossref
Crossref
Melissa D. Chengalroyen, Audrey Jordaan, Ronnett Seldon, Thomas Ioerger, Scott G. Franzblau, Mohamed Nasr, Digby F. Warner & Valerie Mizrahi. (2020) Biological Profiling Enables Rapid Mechanistic Classification of Phenotypic Screening Hits and Identification of KatG Activation-Dependent Pyridine Carboxamide Prodrugs With Activity Against Mycobacterium tuberculosis. Frontiers in Cellular and Infection Microbiology 10.
Crossref
Crossref
Tirosh Shapira, Leah Rankine-Wilson, Joseph D. Chao, Virginia Pichler, Celine Rens, Tom Pfeifer & Yossef Av-Gay. (2020) High-Content Screening of Eukaryotic Kinase Inhibitors Identify CHK2 Inhibitor Activity Against Mycobacterium tuberculosis. Frontiers in Microbiology 11.
Crossref
Crossref
Elisa Rampacci, Valentina Stefanetti, Fabrizio Passamonti & Marcela Henao-Tamayo. (2020) Preclinical Models of Nontuberculous Mycobacteria Infection for Early Drug Discovery and Vaccine Research. Pathogens 9:8, pages 641.
Crossref
Crossref